Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Tricida Inc (TCDA)

Tricida Inc (TCDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,012
  • Shares Outstanding, K 55,669
  • Annual Sales, $ 0 K
  • Annual Income, $ -176,570 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.22
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.44
  • Most Recent Earnings $-0.44 on 11/14/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.43
  • Number of Estimates 1
  • High Estimate -0.43
  • Low Estimate -0.43
  • Prior Year -0.92
  • Growth Rate Est. (year over year) +53.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0922 +17.14%
on 01/23/23
0.2591 -58.32%
on 01/12/23
-0.0424 (-28.19%)
since 12/23/22
3-Month
0.0922 +17.14%
on 01/23/23
0.8000 -86.50%
on 10/24/22
-10.7720 (-99.01%)
since 10/21/22
52-Week
0.0922 +17.14%
on 01/23/23
13.8500 -99.22%
on 08/24/22
-8.7020 (-98.77%)
since 01/21/22

Most Recent Stories

More News
Tricida Announces Third Quarter 2022 Financial Results

Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three and nine months ended September 30, 2022 and provided an update on key initiatives.

TCDA : 0.1080 (-10.00%)
Tricida Provides Strategic Update

Tricida, Inc. (NASDAQ: TCDA), announced today that the Board of Directors has authorized Tricida to initiate a review of strategic alternatives to maximize stakeholder value. To facilitate this review,...

TCDA : 0.1080 (-10.00%)
Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer

Tricida, Inc. (NASDAQ: TCDA) announced today the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer’s ability to slow CKD progression in patients with metabolic...

TCDA : 0.1080 (-10.00%)
Tricida Announces $125 Million Debt Facility with Hercules Capital

Tricida, Inc. (Nasdaq: TCDA) announced today that it has entered into a debt facility with Hercules Capital, Inc. (NYSE: HTGC), a leader in customizing debt financing for companies in the life sciences...

TCDA : 0.1080 (-10.00%)
HTGC : 19.39 (-0.62%)
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Tricida, Inc. (TCDA) and Encourages Long-Term TCDA Stockholders to Contact the Firm

Kaskela Law LLC announces that it is investigating Tricida, Inc. (“Tricida” or the “Company”) (NASDAQ: TCDA) on behalf of the Company’s long-term investors. The investigation seeks to determine...

TCDA : 0.1080 (-10.00%)
Tricida Announces the Selection of the VALOR-CKD Trial for an Oral Presentation in the High-Impact Clinical Trials Session at ASN Kidney Week 2022

Tricida, Inc. (Nasdaq: TCDA) announced today that a late-breaking clinical trial abstract on the Phase 3, VALOR-CKD renal outcomes trial has been selected by the American Society of Nephrology (ASN) and...

TCDA : 0.1080 (-10.00%)
TRICIDA INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Tricida, Inc. - TCDA

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Tricida, Inc. (NasdaqGS:...

TCDA : 0.1080 (-10.00%)
TRICIDIA INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Tricida, Inc. - TCDA

/PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that...

TCDA : 0.1080 (-10.00%)
Tricida to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference. Tricida will provide a company overview, business update and progress...

TCDA : 0.1080 (-10.00%)
TRICIDA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Tricida, Inc. - TCDA

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Tricida, Inc. (NasdaqGS:...

TCDA : 0.1080 (-10.00%)

Business Summary

Tricida, Inc. is a late-stage pharmaceutical company. It focuses on the discovery and clinical development of novel therapeutics to address renal, metabolic and cardiovascular diseases. The company's product candidate consists of TRC101, a non-absorbed, orally-administered polymer drug designed to treat...

See More

Key Turning Points

3rd Resistance Point 0.1426
2nd Resistance Point 0.1293
1st Resistance Point 0.1187
Last Price 0.1080
1st Support Level 0.0948
2nd Support Level 0.0815
3rd Support Level 0.0709

See More

52-Week High 13.8500
Fibonacci 61.8% 8.5945
Fibonacci 50% 6.9711
Fibonacci 38.2% 5.3477
Last Price 0.1080
52-Week Low 0.0922

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar